FDA Adverse Event Death Summary report: N

THORATEC® HEARTMATE 3® LVAS IMPLANT KIT

MDR report key: 21434608 · Received February 21, 2025

Report

Report Number
2916596-2025-00921
Event Type
Death
Date Received
February 21, 2025
Date of Event
January 1, 2013
Report Date
February 21, 2025
Manufacturer
THORATEC CORPORATION
Product Code
DSQ
UDI-DI
00813024013297
PMA / PMN Number
P160054
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
MI, US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 0

SPECIFIC PATIENT INFORMATION AND DEVICE SERIAL NUMBER ARE DOCUMENTED AS UNKNOWN. DEPARTMENT OF INTERNAL MEDICINE, UNIVERSITY OF MICHIGAN, 1500 E MEDICAL CENTER DRIVE TC 311Q, ANN ARBOR, MI 48109-5853, USA. DIVISION OF CARDIOVASCULAR MEDICINE, UNIVERSITY OF MICHIGAN MEDICAL CENTER, ANN ARBOR, MI 48109-5869, USA. ELECTROPHYSIOLOGY SECTION, DIVISION OF CARDIOVASCULAR MEDICINE, UNIVERSITY OF MICHIGAN, 1425 E. ANN ST. FLOOR 3 RECEPTION C, ANN ARBOR, MI 48103, USA DEPARTMENT OF CARDIOVASCULAR SURGERY, UNIVERSITY OF MICHIGAN, ANN ARBOR, MI 48103, USA. CURTIS, B., DESHMUKH, A., LARSON, J., GHANBARI, H., GHANNAM, M., CRAWFORD, T., LATCHAMSETTY, R., PAGANI, F., BOGUN, F., & LIANG, J. (2024). SAFETY AND HEMODYNAMIC IMPLICATIONS OF TRANSSEPTAL ACCESS FOR VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES. JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 67(6), P.1319-1321. HTTPS://DOI.ORG/10.1007/S10840-024-01768-0. MANUFACTURER¿S INVESTIGATION CONCLUSION: A DIRECT CORRELATION BETWEEN HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEMS (LVAS) AND THE REPORTED EVENTS COULD NOT CONCLUSIVELY BE ESTABLISHED THROUGH THIS EVALUATION. THE SERIAL NUMBERS OF THE HEARTMATE 3 LEFT VENTRICULAR SYSTEMS IN USE WERE NOT PROVIDED. THE HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM (LVAS) INSTRUCTIONS FOR USE (IFU), REVISION D, IS CURRENTLY AVAILABLE. SECTION 1 OF THIS DOCUMENT LISTS ADVERSE EVENTS THAT MAY BE ASSOCIATED WITH THE USE OF THE HEARTMATE 3 LVAS, INCLUDING DEATH. NO FURTHER INFORMATION WAS PROVIDED. THE MANUFACTURER IS CLOSING THE FILE ON THIS EVENT.

Description of Event or Problem · 0

IT WAS REPORTED THROUGH THE RESEARCH ARTICLE ¿SAFETY AND HEMODYNAMIC IMPLICATIONS OF TRANSSEPTAL ACCESS FOR VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES¿ THAT THE HEARTMATE 3 (HM3) MAY BE ASSOCIATED WITH VENTRICULAR TACHYCARDIA, VENTRICULAR ANEURYSM, PULMONARY HYPERTENSION, MODERATE OR SEVERE RIGHT VENTRICLE DYSFUNCTION, TRANSPLANTATION, AND DEATH. A TOTAL OF 15 PATIENTS WITH LVAD UNDERWENT 19 VENTRICULAR TACHYCARDIA ABLATION PROCEDURES WITH SINGLE TRANSSEPTAL ACCESS FOR LEFT VENTRICLE (LV) ABLATION WITHOUT ATRIAL SEPTAL DEFECT (ASD) CLOSURE. LVADS INCLUDED HEARTMATE 3 AND HEARTWARE HVAD. 6 HAD PULMONARY HYPERTENSION, AND 7 HAD MODERATE OR SEVERE RIGHT VENTRICLE DYSFUNCTION. POST-PROCEDURE ECHOCARDIOGRAMS (N = 14; MEDIAN TIME TO ECHO 57 DAYS) SHOWED NO INTRACARDIAC SHUNTING OR PERSISTENT ASD. RIGHT HEART CATHETERIZATION (RHC) (PRE: N = 14; POST: N = 8, AT MEDIAN FOLLOW-UP 92.5 DAYS) SHOWED SIMILAR PRE-AND POST-ABLATION RA PRESSURES (11.5 VS. 12 MMHG, P = 0.17) AND WEDGE PRESSURES (20.5 VS. 19.5 MMHG, P = 0.99). SIGNIFICANT SHUNTING WAS ABSENT ON PRE- VERSUS POST-ABLATION ARTERIAL (MEDIAN 95% VS. 99%) AND PA OXYGEN SATURATIONS (58% VS. 62%). NO CLINICALLY SIGNIFICANT RIGHT-LEFT SHUNTING OR HYPOXIA/HYPOXEMIA OCCURRED POST-ABLATION. OVER MEAN FOLLOW-UP OF 581 ± 418 DAYS AFTER LAST ABLATION, 10 PATIENTS REMAINED ALIVE, 1 OF WHOM UNDERWENT HEART TRANSPLANTATION. 5 PATIENTS DIED DURING FOLLOW-UP (4 FROM CONDITIONS UNRELATED TO ABLATION AND 1 FROM RECURRENT VT). AT 1 YEAR AFTER LAST ABLATION, VA RECURRED IN 5 (30%) PATIENTS (FIG. 1A).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1110632 THORATEC® HEARTMATE 3® LVAS IMPLANT KIT Ventricular (assist) bypass DSQ THORATEC CORPORATION 106524US 00813024013297

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Death